Lasilix Special (Furosemide)

Furosemide blocks the Na⁺/K⁺/2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle. By inhibiting this transporter, it reduces the reabsorption of sodium, chloride, and potassium, leading to increased urinary loss of these electrolytes together with water. The resulting diuresis decreases extracellular fluid volume and systemic vascular resistance.

The dose of Lasilix Special is individualized by the prescribing clinician based on the patient’s medical condition, severity of fluid overload, renal function, and response to therapy. Typical dosing ranges for intravenous administration vary, and the prescriber will determine the appropriate amount, frequency, and duration for each patient.

Safety data for furosemide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefits outweigh the possible risks to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Lasilix Special product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Lasilix Special (furosemide) is a loop diuretic, offering a more potent and rapid diuretic effect than thiazide diuretics, which act on the distal convoluted tubule. Loop diuretics are preferred for severe edema and acute fluid overload, whereas thiazides are often used for milder hypertension. The choice depends on the clinical scenario, renal function, and desired speed of fluid removal.

Lasilix Special should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Ensure the container is tightly sealed when not in use, and keep it out of reach of children. Do not freeze the product, and discard any solution that appears discolored or contains particles.

Lasilix Special is administered intravenously. The solution is typically given as a slow infusion or bolus injection, depending on the clinical indication and patient condition. Administration should be performed by qualified healthcare personnel in a setting equipped for monitoring vital signs and electrolyte levels, with appropriate dilution and infusion equipment as recommended in the product’s prescribing information.

The most serious risks include ototoxicity, which can cause hearing loss especially with rapid IV administration; severe electrolyte disturbances such as hypokalemia, hyponatremia, or hyperuricemia; acute renal failure due to excessive volume depletion; and hypersensitivity reactions that may lead to anaphylaxis. Prompt monitoring of renal function, electrolytes, and auditory status is essential during therapy.

Lasilix Special is contraindicated in patients with anuria (no urine output), known hypersensitivity to furosemide or other sulfonamide-derived drugs, and those with severe electrolyte depletion that cannot be corrected. Caution is also advised for individuals with severe hepatic impairment, uncontrolled hypotension, or active ototoxicity. Clinicians must evaluate each patient’s medical history before initiating therapy.